Client’s Goals

Our client, a leading provider of analytical laboratory instruments and software, engaged MarketsandMarkets to grow revenues. We offered in-depth intelligence into the interconnected ecosystem of our client, client’s clients, and their clients. Our team defined and solved a series of problems for tapping into new opportunities identified. Few of the key problems solved during the engagement are:

• Understanding of the global market for different segments, including biomarkers instruments market, diseases indication and consumables market by application, and consumables market by assay kits & reagents
• Bifurcation of the total biomarker market in drug discovery and development and diagnostics use; the latter being further segmented in research and clinical use
• Detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
• Insights into market share analysis of key players in the mass spectroscopy segment

Our Approach

We leveraged our AI-driven market intelligence platform, KnowledgeStore, for identifying key technologies used in biomarker identification and profiling. Our team further identified key applications and diseases where each of these technologies is used. We interviewed a host of product suppliers and potential customers/end-use industries to understand their unmet needs, possible use cases, and benefits from these technologies as well as what they looked for in a technology partner.

Our analysts expanded the understanding of the market potential across various application areas, including clinical diagnostics, research, and drug discovery. Further, we also helped the client to build an understanding of the competitive landscape, varying business models, and strategies of different players in the biomarker technology market. Our client services team helped the client to devise a differentiated product offering and forge suitable alliances to help them win in this market.

Revenue Shifts Identified

Presently there is an increasing focus on identification of new cancer biomarkers. Checkpoint inhibitors have the fastest growth rate among all the available drug classes against cancer. However, PD1 and L1 are no considered more sufficient. Microsatellite instability (MSI) and deficient MisMatch Repair (dMMR) are now trending. Ongoing research efforts are focusing on understanding potential life-threatening toxicities.

Interconnections

Long-term goals are focused towards development and application of high-dimensional antigen-specific T cell profiling technology; finding novel therapeutic targets such as tumor-derived microvesicles, soluble immune proteins, and metabolites; discovery of more accurate biomarkers of clinical outcomes; and prediction of immune response to Immuno-Oncology (IO) therapies. Owing to this there will be many collaborations/joint clinical efforts between pharma/biopharma and molecular diagnostics provider companies.

Unknowns Identified

The industry is also focusing on CAR-T Cells, Next Generation ADCs, combination strategies to target new biomarkers and tap cohort of patients who are non-responsive to immunotherapies. As the vast majority of cancer deaths are the result of these cells forming new tumors resistant to the drugs, the industry is also trying to overcome resistance of various combinations.

Revenue Impact (RI)

Our insights helped the global leader in the analytical laboratory solutions market to identify new revenue sources in biomarker industry valued at USD 55 million by 2025.